The clinical relevance of the METTL1-TXNDC12-c-Myc axis was substantiated in HNSCC specimens, underlining the potential of targeting this pathway as a therapeutic strategy in HNSCC. This evidence concerns the gene METTL1 and head and neck squamous cell carcinoma.